Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin Diseases AND Plaque Psoriasis AND etanercept

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Skin Diseases AND Plaque Psoriasis AND etanercept. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2018-001021-10 Sponsor Protocol Number: SAHL1011 Start Date*: 2018-08-06
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Brodalumab in a randomised, open, phase IV study evaluating clinical efficacy in psoriasis patients switching from TNF-alpha inhibitor treatment
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020005-32 Sponsor Protocol Number: A3921111 Start Date*: 2011-02-08
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI-SITE, RANDOMIZED, MIXED-BLIND, PARALLEL-GROUP TREATMENT WITHDRAWAL AND RE-TREATMENT STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVE...
    Medical condition: Chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) FI (Completed) SK (Completed) DK (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003214-41 Sponsor Protocol Number: CNTO1959PSA3003 Start Date*: 2019-01-22
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthrit...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) ES (Completed) PL (Completed) PT (Completed) HU (Completed) BG (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002804-42 Sponsor Protocol Number: M-14745-42 Start Date*: 2019-11-27
    Sponsor Name:Almirall S.A.
    Full Title: An international, multicentre, open label, interventional phase IV clinical study to investigate the efficacy and safety of tildrakizumab 100 mg in patients with moderate-to-severe chronic plaque p...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020002-15 Sponsor Protocol Number: A3921061 Start Date*: 2010-11-15
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
    Medical condition: Moderate To Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (Completed) NL (Completed) FI (Prematurely Ended) ES (Completed) DK (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) AT (Completed) GR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000215-92 Sponsor Protocol Number: BYH1003 Start Date*: 2019-07-02
    Sponsor Name:Bay Pharma GmbH
    Full Title: Prospective, randomized, double blinded, placebo controlled, multicentre study for the evaluation of efficacy and safety of a Tacrolimus-containing solution (TACRO-Skin) in subjects with mild to se...
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037157 Psoriasis of scalp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001163-37 Sponsor Protocol Number: CNTO1959PSA3001 Start Date*: 2017-07-25
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis i...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012265-60 Sponsor Protocol Number: CNTO1275PSA3002 Start Date*: 2010-03-22
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ps...
    Medical condition: Psoriatric arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SE (Completed) FR (Completed) GB (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-003551-11 Sponsor Protocol Number: TILD-19-12 Start Date*: 2020-08-17
    Sponsor Name:Sun Pharma Advanced Research Company Ltd.
    Full Title: A Multicenter, Randomized, Placebo and Active Comparator-Controlled Clinical trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects from 6 to <18 Years...
    Medical condition: moderate to severe chronic plaque psoriasis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001368-46 Sponsor Protocol Number: A3921125 Start Date*: 2013-10-23
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONS...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) SK (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005099-36 Sponsor Protocol Number: IM011-055 Start Date*: 2021-08-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: POETYK PsA-2 (055) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Participants with Active Psoriatic Arthritis (Ps...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IT (Completed) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 05:20:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA